Biotech · Private company
Pharvaris Netherlands B.V.
Track this companyFree. Adds Pharvaris Netherlands B.V. to your Dealase workspace and tells you when its record changes.
Clinical trials84 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- deucrictibantPhase 3 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- DeucrictibantPhase 3 · Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)ClinicalTrials.gov · fetched Nov 12, 2026
- DeucrictibantPhase 3 · Hereditary Angioedema (HAE)ClinicalTrials.gov · fetched Nov 12, 2026
- Deucrictibant high dosePhase 2 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- Deucrictibant low dosePhase 2 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyPHASE3 · RECRUITING · started Oct 16, 2025ClinicalTrials.gov NCT07266805 · fetched Nov 12, 2026
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPHASE3 · ENROLLING_BY_INVITATION · started Feb 1, 2025ClinicalTrials.gov NCT06679881 · fetched Nov 12, 2026
- Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPHASE3 · COMPLETED · started Dec 1, 2024ClinicalTrials.gov NCT06669754 · fetched Nov 12, 2026
- Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaPHASE3 · COMPLETED · started Feb 26, 2024ClinicalTrials.gov NCT06343779 · fetched Nov 12, 2026
- Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 ReceptorPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 11, 2023ClinicalTrials.gov NCT05834777 · fetched Nov 12, 2026
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPHASE2_PHASE3 · ENROLLING_BY_INVITATION · started Dec 28, 2022ClinicalTrials.gov NCT05396105 · fetched Nov 12, 2026
- Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IIPHASE2 · TERMINATED · started Apr 19, 2022ClinicalTrials.gov NCT05047185 · fetched Nov 12, 2026
- Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPHASE2 · COMPLETED · started Feb 3, 2021ClinicalTrials.gov NCT04618211 · fetched Nov 12, 2026